Sarepta Therapeutics to Present Company Overview at the Leerink Swann Global Healthcare Conference
Webcast Accessible via Sarepta Therapeutics Website
(firmenpresse) - CAMBRIDGE, MA -- (Marketwire) -- 02/04/13 -- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the Leerink Swann Global Healthcare Conference in New York, NY on Thursday, February 14, 2013 at 2:00 p.m. Eastern Time. Chris Garabedian, Sarepta's President and CEO, will be the presenter.
The presentation will be webcast live under the events section of Sarepta Therapeutics' website at and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at .
Sarepta Investor Contact:
Erin Cox
425.354.5140
Sarepta Media Contact:
Jim Baker
617.444.8424 ext. 3124
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 04.02.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 1193307
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
CAMBRIDGE, MA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 109 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sarepta Therapeutics to Present Company Overview at the Leerink Swann Global Healthcare Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von
Sarepta Therapeutics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
